我武生物
(300357)
| 流通市值：112.64亿 | | | 总市值：121.84亿 |
| 流通股本：4.84亿 | | | 总股本：5.24亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 216,249,528.11 | 848,190,443.3 | 673,790,861.6 | 386,295,265.17 |
| 营业收入 | 216,249,528.11 | 848,190,443.3 | 673,790,861.6 | 386,295,265.17 |
| 二、营业总成本 | 132,389,079.88 | 513,936,550.27 | 373,879,800.68 | 230,624,372.42 |
| 营业成本 | 10,416,061.8 | 40,189,443.39 | 30,963,296.37 | 19,480,788.41 |
| 税金及附加 | 1,292,949.08 | 5,757,458.02 | 3,188,561.77 | 2,162,726.44 |
| 销售费用 | 80,961,800.81 | 323,167,128.64 | 242,620,478.11 | 147,293,829.61 |
| 管理费用 | 16,458,144.99 | 62,108,852.94 | 40,632,817.18 | 26,225,364.98 |
| 研发费用 | 30,563,652.07 | 112,196,011.42 | 78,493,899.35 | 49,591,397.57 |
| 财务费用 | -7,303,528.87 | -29,482,344.14 | -22,019,252.1 | -14,129,734.59 |
| 其中:利息费用 | 319,261.87 | 1,308,407.77 | 915,706.27 | 658,566.37 |
| 其中:利息收入 | 7,764,062.21 | 30,957,179.18 | 23,031,334.64 | 14,846,833.2 |
| 加:公允价值变动收益 | 400,180.79 | -666,941.56 | -1,572,973.11 | -1,212,042.58 |
| 加:投资收益 | -363,771.21 | 1,910,702.96 | 2,362,211.11 | 3,213,674.88 |
| 资产处置收益 | 284,607.11 | - | - | - |
| 资产减值损失(新) | - | -472,549.79 | -472,549.79 | -472,549.79 |
| 信用减值损失(新) | -1,882,028.87 | 903,313.21 | -2,949,561.24 | 78,067.77 |
| 其他收益 | 5,706,164.22 | 9,044,935.16 | 3,309,625.37 | 2,432,345.53 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 88,005,600.27 | 344,973,353.01 | 300,587,813.26 | 159,710,388.56 |
| 加:营业外收入 | 117,418.65 | 1,777,892.77 | 1,055,081.51 | 988,718.87 |
| 减:营业外支出 | 327,397.08 | 795,742.84 | 180,716.08 | 100,615.18 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 87,795,621.84 | 345,955,502.94 | 301,462,178.69 | 160,598,492.25 |
| 减:所得税费用 | 13,879,737.29 | 50,433,428.86 | 41,680,386.91 | 18,885,932.61 |
| 六、净利润 | 73,915,884.55 | 295,522,074.08 | 259,781,791.78 | 141,712,559.64 |
| 持续经营净利润 | 73,915,884.55 | 295,522,074.08 | 259,781,791.78 | 141,712,559.64 |
| 归属于母公司股东的净利润 | 77,207,320.73 | 310,184,878.02 | 270,147,812.94 | 148,604,514.09 |
| 少数股东损益 | -3,291,436.18 | -14,662,803.94 | -10,366,021.16 | -6,891,954.45 |
| (一)基本每股收益 | 0.15 | 0.59 | 0.52 | 0.28 |
| (二)稀释每股收益 | 0.15 | 0.59 | 0.52 | 0.28 |
| 八、其他综合收益 | 5,347,832.68 | 4,321.02 | 8,112.2 | 9,561.78 |
| 归属于母公司股东的其他综合收益 | 5,347,832.68 | 4,321.02 | 8,112.2 | 9,561.78 |
| 九、综合收益总额 | 79,263,717.23 | 295,526,395.1 | 259,789,903.98 | 141,722,121.42 |
| 归属于母公司股东的综合收益总额 | 82,555,153.41 | 310,189,199.04 | 270,155,925.14 | 148,614,075.87 |
| 归属于少数股东的综合收益总额 | -3,291,436.18 | -14,662,803.94 | -10,366,021.16 | -6,891,954.45 |
| 公告日期 | 2024-04-19 | 2024-04-19 | 2023-10-26 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |